NCT05763641 TAD After Chemotherapy in Locally Advanced Breast Cancer
| NCT ID | NCT05763641 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hospital Universitari de Bellvitge |
| Condition | Sentinel Lymph Node |
| Study Type | OBSERVATIONAL |
| Enrollment | 162 participants |
| Start Date | 2021-02-01 |
| Primary Completion | 2026-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 162 participants in total. It began in 2021-02-01 with a primary completion date of 2026-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an observational study to validate target axillary dissection (TAD) in locally advanced tumors (cN2 and/or cT4).
Eligibility Criteria
Inclusion Criteria: * Axillary lymph node metastasis proven by cytology * Clinical or radiological N2a (at least 4 suspicious lymph nodes on axillary ultrasound at diagnosis) * Extensive T4 subsidiary to axillary lymphadenectomy according to current clinical criteria * Neoadjuvant chemotherapy Exclusion Criteria: * cN3 verified by imaging tests * N2 due to internal mammary involvement (N2b). * Tumors whose surrogate molecular subtype is luminal A. * Patients undergoing neoadjuvant endocrine therapy * Patients with local recurrences and metastatic tumors.
Contact & Investigator
amparo Garcia-Tejedor, MDPhD
PRINCIPAL INVESTIGATOR
Instituto de Investigación Biomédica de Bellvitge (IDIBELL)
Frequently Asked Questions
Who can join the NCT05763641 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Sentinel Lymph Node. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05763641 currently recruiting?
Yes, NCT05763641 is actively recruiting participants. Contact the research team at agarciat@bellvitgehospital.cat for enrollment information.
Where is the NCT05763641 trial being conducted?
This trial is being conducted at L'Hospitalet de Llobregat, Spain, Barcelona, Spain.
Who is sponsoring the NCT05763641 clinical trial?
NCT05763641 is sponsored by Hospital Universitari de Bellvitge. The principal investigator is amparo Garcia-Tejedor, MDPhD at Instituto de Investigación Biomédica de Bellvitge (IDIBELL). The trial plans to enroll 162 participants.